Physicians' Academy for Cardiovascular Education

SGLT2 inhibition in the management of type 2 diabetes: Potential impact on CVD Risk

Prof Silvio E Inzucchi, Yale Diabetes Center, New Haven, CT, USA

10' education - Sep. 29, 2015

Video navigation menu

  • T2DM pathogenesis 00:01
  • SGLT2 Inhibitors: How do they work? 06:53
  • Potential pathways to CV benefits of SGLT2-inhibitors based on clinical and mechanistic studies 11:01
  • SGLT2 inhibitors and the kidney 16:20
  • SGLT2 Inhibitors: Risks & Benefits  19:08
  • 2015 ADA-EASD Position Statement on Management of Hyperglycemia in T2DM 22:40

The content is aimed for medical professionals. To view this item member registration is needed. Register for free to get unlimited access to our educational resources.
The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: